Kainos Medicine Inc Market Cap ($24.10 Million)
Market Cap & Net Worth: Kainos Medicine Inc (284620)
Kainos Medicine Inc market cap. Kainos Medicine Inc (KQ:284620) has a market capitalization of $24.10 Million (₩35.56 Billion) as of November 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #24355 globally and #1734 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kainos Medicine Inc's stock price ₩1087.00 by its total outstanding shares 32711400 (32.71 Million). Also see 284620 operating cash flow for how efficiently the company converts equity into cash flow.
Kainos Medicine Inc Market Cap History (2018–2025)
Kainos Medicine Inc market cap history from 2018 to 2025. Data shows change from $212.37 Million to $24.10 Million (-25.94% CAGR). Check Kainos Medicine Inc share price for real-time trading data and today's change.
Index Memberships
Kainos Medicine Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$203.83 Billion | 0.01% | #896 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$203.83 Billion | 0.01% | #896 of 1384 |
Weight: Kainos Medicine Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kainos Medicine Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kainos Medicine Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Kainos Medicine Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.12x
Kainos Medicine Inc's market cap is 0.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $265.07 Million | $1.66 Billion | -$16.21 Billion | 0.16x | N/A |
| 2022 | $90.89 Million | $130.02 Million | -$15.88 Billion | 0.70x | N/A |
| 2023 | $95.77 Million | $267.31 Million | -$15.24 Billion | 0.36x | N/A |
| 2024 | $70.27 Million | $590.37 Million | -$12.19 Billion | 0.12x | N/A |
Competitor Companies of 284620 by Market Capitalization
Companies near Kainos Medicine Inc in the global market cap rankings as of November 5, 2026. Also see Kainos Medicine Inc asset portfolio for a full breakdown of the balance sheet.
Key companies related to Kainos Medicine Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Kainos Medicine Inc (2018–2025)
Market capitalization of Kainos Medicine Inc from 2018 to today. Between 2018 and today, Kainos Medicine Inc's market cap moved from $212.37 Million to $ 24.10 Million, with a yearly change of -25.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | ₩24.10 Million | -65.71% |
| 2024 | ₩70.27 Million | -26.62% |
| 2023 | ₩95.77 Million | +5.37% |
| 2022 | ₩90.89 Million | -65.71% |
| 2021 | ₩265.07 Million | -43.56% |
| 2020 | ₩469.61 Million | +114.29% |
| 2019 | ₩219.15 Million | +3.19% |
| 2018 | ₩212.37 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 13th, 2026 the market cap of Kainos Medicine Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $24.10 Million USD |
| MoneyControl | $24.10 Million USD |
| MarketWatch | $24.10 Million USD |
| marketcap.company | $24.10 Million USD |
| Reuters | $24.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kainos Medicine Inc
Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to tre… Read more